TapewireFind a company

person · Reporting owner

Lettmann Jason

Disclosed activity across 2 companies

Tapewire entity
22280
SEC CIK
0001688269

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040Director · CHIEF EXECUTIVE OFFICERAugust 17, 2026August 18, 2026
Ra Pharmaceuticals, Inc.RARX · Entity 150034Director · 10% ownerJune 20, 2017June 22, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALX ONCOLOGY HOLDINGS INC

Report date August 17, 2026 · Filed August 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect294,379 Reported balance After 2026-08-17 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-08-17 · Sale · Disposed 2,230 · Balance 294,379

F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

F2: Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

F2: Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2026.

Ra Pharmaceuticals, Inc.

Report date June 20, 2017 · Filed June 22, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $22.37 · Expires 2027-06-20Direct15,000 Reported balance After 2017-06-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2017-06-20 · Grant · Acquired 15,000 · Balance 15,000

F1: On June 20, 2017, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 20, 2017 or (ii) the Issuer's annual general meeting of shareholders in 2018.

F2: The reporting person is a member of Morgenthaler Advisors IX, LLC ("MA IX"), which is the investment adviser of Morgenthaler Venture Partners IX, LP ("MVP IX"). Pursuant to the limited partnership agreement of MVP IX and the limited liability company agreement of MA IX, the reporting person is deemed to hold the option for the benefit of MVP IX. Upon exercise of the option, the shares will be transferred to MA IX, and the value of such shares will reduce the management fees payable to MA IX by MVP IX. As such, MVP IX is entitled to the economic benefits of the option and the reporting person disclaims beneficial ownership of the option.

Filing footnotes · ownership attribution and instrument terms

F1: On June 20, 2017, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 20, 2017 or (ii) the Issuer's annual general meeting of shareholders in 2018.

F2: The reporting person is a member of Morgenthaler Advisors IX, LLC ("MA IX"), which is the investment adviser of Morgenthaler Venture Partners IX, LP ("MVP IX"). Pursuant to the limited partnership agreement of MVP IX and the limited liability company agreement of MA IX, the reporting person is deemed to hold the option for the benefit of MVP IX. Upon exercise of the option, the shares will be transferred to MA IX, and the value of such shares will reduce the management fees payable to MA IX by MVP IX. As such, MVP IX is entitled to the economic benefits of the option and the reporting person disclaims beneficial ownership of the option.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries C Convertible Preferred Stock · Derivative 664,660 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 20

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 664,660 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F9 · ownership.nature: The shares are held of record by Lightstone Ventures II, LP (LV II LP). As a managing director of LSV Associates II, LLC (LSV Associates II), the General Partner of LV II LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries C Convertible Preferred Stock · Derivative 18,705 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 19

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 18,705 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F8 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries C Convertible Preferred Stock · Derivative 137,286 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 18

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 137,286 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F6 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries C Convertible Preferred Stock · Derivative 10,529 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 17

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,529 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries B Convertible Preferred Stock · Derivative 11,110 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 16

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 11,110 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F11 · ownership.nature: The shares are held of record by Lightstone Ventures II(A), LP (LV II(A) LP). As a managing director of LSV Associates II, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries B Convertible Preferred Stock · Derivative 150,801 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 15

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 150,801 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F9 · ownership.nature: The shares are held of record by Lightstone Ventures II, LP (LV II LP). As a managing director of LSV Associates II, LLC (LSV Associates II), the General Partner of LV II LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries B Convertible Preferred Stock · Derivative 8,175 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 14

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 8,175 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F8 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries B Convertible Preferred Stock · Derivative 59,998 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 13

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 59,998 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F6 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries A Convertible Preferred Stock · Derivative 39,758 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 12

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 39,758 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F11 · ownership.nature: The shares are held of record by Lightstone Ventures II(A), LP (LV II(A) LP). As a managing director of LSV Associates II, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries A Convertible Preferred Stock · Derivative 683,523 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 11

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 683,523 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F9 · ownership.nature: The shares are held of record by Lightstone Ventures II, LP (LV II LP). As a managing director of LSV Associates II, LLC (LSV Associates II), the General Partner of LV II LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries A Convertible Preferred Stock · Derivative 222,752 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 10

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 222,752 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F8 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries A Convertible Preferred Stock · Derivative 1,633,743 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 9

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,633,743 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F6 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries A Convertible Preferred Stock · Derivative 78,175 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 8

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 78,175 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionCommon Stock 111,528 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · nonDerivative · entry 7

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 120,212

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F12 · balance_after: Includes 8,684 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020.

F11 · ownership.nature: The shares are held of record by Lightstone Ventures II(A), LP (LV II(A) LP). As a managing director of LSV Associates II, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 PurchaseCommon Stock 22,000 $19.00 $418,000.00
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · nonDerivative · entry 6

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 22,000

F11 · ownership.nature: The shares are held of record by Lightstone Ventures II(A), LP (LV II(A) LP). As a managing director of LSV Associates II, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionCommon Stock 1,498,984 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · nonDerivative · entry 5

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,023,469

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F10 · balance_after: Includes 146,485 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020.

F9 · ownership.nature: The shares are held of record by Lightstone Ventures II, LP (LV II LP). As a managing director of LSV Associates II, LLC (LSV Associates II), the General Partner of LV II LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 PurchaseCommon Stock 378,000 $19.00 $7,182,000.00
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · nonDerivative · entry 4

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 378,000

F9 · ownership.nature: The shares are held of record by Lightstone Ventures II, LP (LV II LP). As a managing director of LSV Associates II, LLC (LSV Associates II), the General Partner of LV II LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionCommon Stock 249,632 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · nonDerivative · entry 3

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 309,222

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F7 · balance_after: Includes 59,590 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020.

F8 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionCommon Stock 1,831,027 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · nonDerivative · entry 2

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,268,087

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F5 · balance_after: Includes 437,060 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020.

F6 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 22, 2020 01:31 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionCommon Stock 88,704 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019931 · doc4.xml · nonDerivative · entry 1

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,220

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F3 · balance_after: Includes 18,516 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020.

Read SEC document
July 16, 2020 Filed Jul 17, 2020 23:06 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 GrantStock Option (right to buy) · Derivative 24,009 $0.00 Strike: $19.00 $0.00
Disclosure

SEC source: 0000899243-20-019579 · doc4.xml · derivative · entry 1

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,009

Underlying: Common Stock · 24,009 shares

Expires 2030-07-16

F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal monthly installments beginning on August 16, 2020.

Read SEC document
June 20, 2017 Filed Jun 22, 2017 23:41 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 GrantOptions to Purchase Common Stock · Derivative 15,000 $0.00 Strike: $22.37 $0.00
Disclosure

SEC source: 0001104659-17-041012 · a4.xml · derivative · entry 1

Lettmann Jason · CIK 0001688269 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-06-20

F1 · derivative.exercise_date: On June 20, 2017, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 20, 2017 or (ii) the Issuer's annual general meeting of shareholders in 2018.

F2 · ownership.direct: The reporting person is a member of Morgenthaler Advisors IX, LLC ("MA IX"), which is the investment adviser of Morgenthaler Venture Partners IX, LP ("MVP IX"). Pursuant to the limited partnership agreement of MVP IX and the limited liability company agreement of MA IX, the reporting person is deemed to hold the option for the benefit of MVP IX. Upon exercise of the option, the shares will be transferred to MA IX, and the value of such shares will reduce the management fees payable to MA IX by MVP IX. As such, MVP IX is entitled to the economic benefits of the option and the reporting person disclaims beneficial ownership of the option.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 ConversionSeries B-2 Preferred Stock · Derivative 481,503 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · derivative · entry 20

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 68,786 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F5 · price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F5 · derivative.exercise_date: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F5 · derivative.expiration_date: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F7 · ownership.nature: Shares held by Lightstone Ventures (A), L.P. LSV GP is the General Partner of Lightstone Ventures (A), L.P. ("LSV-A"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV-A except to the extent of their pecuniary interest therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 ConversionSeries B-1 Preferred Stock · Derivative 3,533,875 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · derivative · entry 19

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 504,839 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F4 · price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F4 · derivative.exercise_date: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F4 · derivative.expiration_date: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F6 · ownership.nature: Shares held by Lightstone Ventures, L.P. LSV Associates, LLC, or LSV GP, is the General Partner of Lightstone Ventures, L.P. ("LSV"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV except to the extent of their pecuniary interest therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 ConversionSeries B-2 Preferred Stock · Derivative 517,617 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · derivative · entry 18

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 73,945 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F5 · price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F5 · derivative.exercise_date: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F5 · derivative.expiration_date: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F7 · ownership.nature: Shares held by Lightstone Ventures (A), L.P. LSV GP is the General Partner of Lightstone Ventures (A), L.P. ("LSV-A"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV-A except to the extent of their pecuniary interest therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 ConversionSeries B-1 Preferred Stock · Derivative 3,798,914 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · derivative · entry 17

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 542,702 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F4 · price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F4 · derivative.exercise_date: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F4 · derivative.expiration_date: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F6 · ownership.nature: Shares held by Lightstone Ventures, L.P. LSV Associates, LLC, or LSV GP, is the General Partner of Lightstone Ventures, L.P. ("LSV"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV except to the extent of their pecuniary interest therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 ConversionSeries B-2 Preferred Stock · Derivative 3,408,439 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · derivative · entry 16

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 486,919 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F5 · price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F5 · derivative.exercise_date: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F5 · derivative.expiration_date: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 ConversionSeries B-1 Preferred Stock · Derivative 3,664,071 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · derivative · entry 15

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 523,438 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F4 · price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F4 · derivative.exercise_date: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F4 · derivative.expiration_date: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 ConversionSeries A Preferred Stock · Derivative 9,744,916 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · derivative · entry 14

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,392,130 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F3 · price: Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F3 · derivative.exercise_date: Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F3 · derivative.expiration_date: Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 OtherWarrants to Purchase Common Stock · Derivative 63,019 $0.00 Strike: $0.07 $0.00
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · derivative · entry 13

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 63,019 shares

Expires 2022-04-01

F2 · derivative.exercise_price: The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares.

F2 · derivative.exercise_date: The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares.

F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 PurchaseCommon Stock 15,633 $13.00 $203,229.00
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 12

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,066,503

F7 · ownership.nature: Shares held by Lightstone Ventures (A), L.P. LSV GP is the General Partner of Lightstone Ventures (A), L.P. ("LSV-A"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV-A except to the extent of their pecuniary interest therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 PurchaseCommon Stock 114,752 $13.00 $1,491,776.00
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 11

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,050,870

F6 · ownership.nature: Shares held by Lightstone Ventures, L.P. LSV Associates, LLC, or LSV GP, is the General Partner of Lightstone Ventures, L.P. ("LSV"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV except to the extent of their pecuniary interest therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 PurchaseCommon Stock 263,538 $13.00 $3,425,994.00
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 10

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,936,118

F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 ConversionCommon Stock 68,786 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 9

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,672,580

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F7 · ownership.nature: Shares held by Lightstone Ventures (A), L.P. LSV GP is the General Partner of Lightstone Ventures (A), L.P. ("LSV-A"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV-A except to the extent of their pecuniary interest therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 ConversionCommon Stock 504,839 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 8

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,603,794

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F6 · ownership.nature: Shares held by Lightstone Ventures, L.P. LSV Associates, LLC, or LSV GP, is the General Partner of Lightstone Ventures, L.P. ("LSV"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV except to the extent of their pecuniary interest therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 ConversionCommon Stock 73,945 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 7

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,098,955

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F7 · ownership.nature: Shares held by Lightstone Ventures (A), L.P. LSV GP is the General Partner of Lightstone Ventures (A), L.P. ("LSV-A"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV-A except to the extent of their pecuniary interest therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 ConversionCommon Stock 542,702 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 6

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,025,010

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F6 · ownership.nature: Shares held by Lightstone Ventures, L.P. LSV Associates, LLC, or LSV GP, is the General Partner of Lightstone Ventures, L.P. ("LSV"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV except to the extent of their pecuniary interest therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 ConversionCommon Stock 486,919 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 5

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,482,308

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 ConversionCommon Stock 523,438 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 4

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,995,389

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 ConversionCommon Stock 1,392,130 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 3

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,471,951

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date.

F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 SaleCommon Stock 340 $13.00 $4,420.00
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 2

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 79,821

F2 · kind: The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares.

F2 · price: The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares.

F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein.

Read SEC document
October 31, 2016 Filed Oct 31, 2016 20:51 UTC Ra Pharmaceuticals, Inc. RARX · Entity 150034 OtherCommon Stock 63,019 $0.07 $4,411.33
Disclosure

SEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 1

Lettmann Jason · CIK 0001688269 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 80,161

F2 · price: The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares.

F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.